Johnson & Johnson forecast 2020 profit below Wall Street estimates and said increased competition for the company’s off-patent treatments could somewhat limit growth in the top-earning pharmaceuticals unit.
Pfizer Inc. forecast 2019 profit and sales below Wall Street estimates as the company expects to take a blow from a stronger dollar and as well as the loss of patent on the blockbuster pain treatment Lyrica during 2019.
The U.S. Food and Drug Administration declined to approve Aquestive Therapeutics Inc.’s erectile dysfunction treatment tadalafil and sought additional data.
An immunotherapy cocktail from Roche helped slow an aggressive type of breast cancer where new treatments have proven elusive.
A drug cocktail with Roche’s Tecentriq added two months to small-cell lung cancer patients’ lives, according to a study, aiding the Swiss group’s bid to win approval in a niche disease area before rivals that now dominate the immunotherapy market.
Europe approved a fifth copy of AbbVie’s $18-billion-a-year biologic Humira – the world’s best-selling prescription medicine – ramping up competition among makers of less-expensive biotech drugs.
Novartis’ generics unit won a European panel’s recommendation for its biosimilar version of AbbVie’s Humira as the Swiss drugmaker aims to take a bite out of sales of the world’s best-selling medicine.
After six months, Teva Pharmaceutical’s search ended as the company hired a new chief executive officer.
Pfizer’s second-quarter 2017 revenue missed Wall Street estimates, hurt by falling demand for its blockbuster pneumonia vaccine Prevnar as well as older drugs.
The U.S. FDA is taking two new, important steps to increase competition in the market for prescription drugs and facilitate entry of lower-cost alternatives.